Cover Image

Comparative utcomes of neoadjuvant treatment prior to total mesorectal excision and total mesorectal excision alone in selected stage II/III low and mid rectal cancer

Current guidelines advocate that all rectal cancer patients with American Joint Committee on Cancer (AJCC) stages II and III disease should be subjected to neoadjuvant therapy. However, improvements in surgical technique have resulted in single-digit local recurrence rates with surgery only.

Saved in:
Bibliographic Details
Main Authors: Kulu, Yakup (Author) , Tarantino, Ignazio (Author) , Billeter, Adrian (Author) , Diener, Markus K. (Author) , Schmidt, Thomas (Author) , Büchler, Markus W. (Author) , Ulrich, Alexis (Author)
Format: Article (Journal)
Language:English
Published: 2016
In: Annals of surgical oncology
Year: 2016, Volume: 23, Issue: 1, Pages: 106-113
ISSN:1534-4681
DOI:10.1245/s10434-015-4832-5
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1245/s10434-015-4832-5
Verlag, lizenzpflichtig, Volltext: https://link.springer.com/article/10.1245%2Fs10434-015-4832-5
Get full text
Author Notes:Yakup Kulu, Ignazio Tarantino, Adrian T. Billeter, Markus K. Diener, Thomas Schmidt, Markus W. Büchler, and Alexis Ulrich
Description
Summary:Current guidelines advocate that all rectal cancer patients with American Joint Committee on Cancer (AJCC) stages II and III disease should be subjected to neoadjuvant therapy. However, improvements in surgical technique have resulted in single-digit local recurrence rates with surgery only.
Item Description:Online veröffentlicht: 25. August 2015
Gesehen am 02.06.2020
Physical Description:Online Resource
ISSN:1534-4681
DOI:10.1245/s10434-015-4832-5

Similar Items